Proteasome inhibition measurements: Clinical application

Eric S. Lightcap, Teresa A. McCormack, Christine S. Pien, Vincent Chau, Julian Adams, Peter J. Elliott

Research output: Contribution to journalArticle

255 Scopus citations

Abstract

Background: PS-341, a selective inhibitor of the proteasome, currently is under evaluation as an anticancer agent in multiple phase I clinical trials. In animal-model studies, PS-341 was rapidly removed from the vascular compartment and distributed widely, quickly approaching the limits of detection. An accurate pharmacodynamic assay has been developed as an alternative or complement to pharmacokinetic measurements. Methods: Fluorogenic kinetic assays for both the chymotryptic and tryptic activities of the proteasome have been optimized for both whole blood and blood cells. Using the ratio of these activities and the catalytic mechanism of the proteasome, we developed a novel method of calculating percentage of inhibition, using two structurally unrelated inhibitors (PS-341 and lactacystin). Results: This ratio method was demonstrated to be sensitive (detection limit of 13% inhibition with 10 μg of cell lysate), specific to the proteasome (PS-341 provides >98% inhibition), accurate (112% analyte recovery), and precise (0% ± 5% inhibition at 0 nmol/L PS-341 and 74.5% ± 1.7% inhibition at 200 nmol/L PS-341). Using these assays, we found that both erythrocytes and leukocytes contain proteasome at 3 μmol/L. Pharmacodynamic results for PS-341 obtained from the whole-blood ratio method were comparable to those using leukocytes determined by another method. Conclusions: The described assay provides a reliable method for studying the pharmacodynamics of proteasome inhibitors and is now in use in concurrent phase I clinical trials with PS-341. (C) 2000 American Association for Clinical Chemistry.

Original languageEnglish (US)
Pages (from-to)673-683
Number of pages11
JournalClinical chemistry
Volume46
Issue number5
DOIs
StatePublished - 2000

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Proteasome inhibition measurements: Clinical application'. Together they form a unique fingerprint.

  • Cite this

    Lightcap, E. S., McCormack, T. A., Pien, C. S., Chau, V., Adams, J., & Elliott, P. J. (2000). Proteasome inhibition measurements: Clinical application. Clinical chemistry, 46(5), 673-683. https://doi.org/10.1093/clinchem/46.5.673